Matinas BioPharma Holdings Inc (MTNB) Stock Analysis

Matinas BioPharma Holdings Inc (MTNB) is a publicly traded company in the HEALTHCARE sector. It trades at $0.79, carries a market capitalization of $5.59M. This page summarizes the public market data, fundamentals, and frequently asked questions for MTNB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

Market Sentiment

Matinas BioPharma Holdings Inc currently has a Neutral sentiment score of -0.10.

About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company headquartered in Bedminster, New Jersey, specializing in the development of innovative oral lipid-based delivery systems for therapeutics targeting infectious diseases and chronic conditions. The company aims to enhance treatment efficacy and patient adherence through its proprietary formulations, which are tailored to address significant unmet medical needs. With an expanding pipeline of candidate products ...

GNG Research Analysis

GNG Research scores Matinas BioPharma Holdings Inc (MTNB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MTNB.

Frequently Asked Questions

Does MTNB pay dividends?

Matinas BioPharma Holdings Inc (MTNB) does not currently pay a regular dividend.

What is MTNB's market cap?

Matinas BioPharma Holdings Inc (MTNB) has a market capitalization of $5.59M with a current stock price of $0.79.